Bivalirudin for Primary Percutaneous Coronary Interventions

Bivalirudin in percutaneous coronary intervention

Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). Results of clinical trials to date suggest bivalirudin is a viable alternative to the use of a heparin combined with a glycoprot...

Improving outcomes with bivalirudin in primary percutaneous coronary intervention.

Optimal pharmacotherapy is essential to realize the bestoutcomes in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). In this regard, effectively restoring reperfusion and maintaining the patency of the infarct artery after stenting requires a balance between the haemorrhagic risks and the ischaemic benefits of anticoagu...

Letter by Johnson et al regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".

BACKGROUND Data from randomized trials has demonstrated the superiority of bivalirudin to glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous coronary intervention. Real-world performance of bivalirudin in primary percutaneous coronary intervention and the benefit of bivalirudin over heparin remain unknown in an era of routine dual antiplatelet therapy. M...

Response to letter regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions

INTRODUCTION Studies have demonstrated bivalirudin efficacy in some patients at increased risk of bleeding. The aim of this study was to determine the extent to which bleeding reduction is achieved among all patients using bivalirudin as compared with a heparin with or without 2B3A inhibitor strategy. METHODS This is a real-world, large-scale retrospective study utilising the American College...